1      0

242 - New Drug Therapies for Alzheimer's Disease

‐ Oct 1, 2021 3:15pm

Credits: None available.

This session discusses the use of monoclonal antibodies in the treatment of Alzheimer’s disease, including risks and benefits, as published in the literature.

Continuing Education Instructions and Disclosure Information:

Contact hours available until 10/2/2023.

Requirements for Successful Completion:

Complete the learning activity in its entirety and complete the online nursing continuing professional development (NCPD) evaluation. You will be able to print your NCPD certificate at any time after you complete the evaluation.

Faculty, Planners, and Speakers Conflict of Interest Disclosure:

Conference Planning Committee Disclosures:

No planning committee member discloses any actual or potential conflict of interest.

Abstract Reviewers:
Margaret Bowers, DNP, FNP-BC, FAANP, FAAN discloses that she serves as an NPACE consultant on cardiology topics for primary care.
No other abstract reviewer discloses any actual or potential conflict of interest.

Speakers Conflict of Interest Disclosure:
Carolyn Clevenger, DNP, RN, GNP-BC, AGPCNP-BC, FAANP, FGSA, FAAN discloses that she has served and received other/financial material support (honoraria for meetings) as a participant on the advisory council for Genentech, maker of a monoclonal antibody treatment for Alzheimer's disease. Participation is limited to discussion of clinician perspectives on the treatment of Alzheimer's disease. She does not receive financial benefit from the sale or marketing of any drug.
No other speaker discloses any actual or potential conflict of interest.

Commercial Support and Sponsorship:
No commercial support or sponsorship declared.

Accreditation Statement:
This educational activity is jointly provided by Anthony J. Jannetti, Inc. (AJJ) and the Gerontological Advanced Practice Nurses Association (GAPNA).

Anthony J Jannetti, Inc. is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Anthony J. Jannetti, Inc. is a provider approved by the California Board of Registered Nursing, Provider Number CEP5387.

Learning Outcome:

After completing this learning activity, the participant will be able to outline the risks and benefits of monoclonal antibody therapies in Alzheimer's disease and describe the challenges of identifying appropriate patients for new monoclonal antibody treatments.


Credits Available

New Drug Therapies for Alzheimer's Disease

You must be logged in and own this session in order to post comments.